We use essential cookies to run this site and cookie-free visitor statistics, which you can switch off. Marketing cookies only with your consent. Cookie policy

EssentialAlways on

Keep the site secure and working, and remember your cookie choice.

Visitor statistics

Cookie-free counts of which pages are used and how fast they load, so we can improve them. On unless you switch it off.

Marketing

Measure our campaigns on other sites, such as LinkedIn. Off until you allow it.

Blog

CellNet™ makes its debut at ISBT 2026 in Kuala Lumpur, with its research published in Vox Sanguinis

Our first international congress for CellNet™: a booth at KLCC, poster P388 on our supercritical CO₂ filter, and the research published in ISBT’s journal.

Sangtech Lab Inc.Published · 4 min read
Two members of the Sangtech team at the Sangtech booth at ISBT 2026, with CellNet™ filters and collection sets on the counter and a meeting under way behind them
The Sangtech booth (O56) at the 39th ISBT International Congress, Kuala Lumpur Convention Centre, June 2026.

In brief

  • Sangtech debuted CellNet™ at the 39th International Congress of the ISBT, June 20–24, 2026, at the Kuala Lumpur Convention Centre.
  • Our poster P388 presented a supercritical CO₂-modified leukoreduction filter with enhanced microparticle removal.
  • The abstract is published in Vox Sanguinis, the journal of the International Society of Blood Transfusion.

KUALA LUMPUR, June 26, 2026. This week Sangtech took CellNet™ to its first international congress. At the 39th International Congress of the International Society of Blood Transfusion (ISBT), held June 20–24 at the Kuala Lumpur Convention Centre (KLCC) with the Malaysian Blood Transfusion Society, we ran a booth, presented a poster and met the people who make and use blood components around the world.

A booth at KLCC

At booth O56, visitors could handle CellNet™ filters and see them built into whole blood collection sets. Our team spent the congress in conversation with blood center staff, set manufacturers and researchers about what one filtration step at the whole blood stage can do for the red cells and plasma a donation becomes.

The booth also carried our new Edison Awards Silver, presented in April for the process behind CellNet™.

Poster P388: the research

Our poster, P388, presented “A Novel Supercritical CO₂-Modified Leukoreduction Filter with Enhanced Microparticle Removal”. The study was carried out with National Taiwan University, National Taiwan University Hospital and Taipei Medical University.

Two members of Sangtech’s R&D team giving a thumbs-up beside poster P388 at ISBT 2026
Figure 1Sangtech’s two heads of R&D beside poster P388, “A Novel Supercritical CO₂-Modified Leukoreduction Filter with Enhanced Microparticle Removal”.
Two members of Sangtech’s R&D team giving a thumbs-up beside poster P388 at ISBT 2026

Figure 1Sangtech’s two heads of R&D beside poster P388, “A Novel Supercritical CO₂-Modified Leukoreduction Filter with Enhanced Microparticle Removal”.

The study looked at supercritical CO₂-assisted impregnation as a sustainable, solvent-free way to modify the polymer nonwovens inside a leukocyte filter, and evaluated a prototype filter for leukocyte removal, red cell recovery and microparticle reduction across storage conditions and blood products.

  • Leukocytes: residual leukocytes below 1 × 10⁶ per unit, with high red cell recovery and practical filtration times, for both whole blood and pre-storage packed red cells.
  • Microparticles: storage microparticles reduced by 70–83% (manufacturer data).
  • Safety: extracts of the modified material showed no cytotoxic response, with cell viability above 90%.

Published in Vox Sanguinis

The abstract is published in Vox Sanguinis, the journal of the International Society of Blood Transfusion, in its ISBT 2026 congress abstracts. It puts the science behind CellNet™ on the record for the transfusion medicine community.

With our research partners

The work behind the poster was a collaboration. In Kuala Lumpur, the Sangtech team joined Professor Thierry Burnouf and his colleagues, who worked with us on the study, for dinner to mark the congress and plan what comes next.

Sangtech’s technology, made in Taiwan

CellNet™ is Sangtech’s technology and a trademark of Sangtech Lab Inc. Sangtech developed it and holds the patents on its supercritical CO₂ process in Taiwan, the United States, Korea and Japan. CellNet™ PR is the first and only commercial whole blood inline leukoreduction filter in the world manufactured without organic solvents or process wastewater.

CellNet™ media is made at our ISO 13485 plant in Yilan, Taiwan, and built into CellNet™ PR, an inline whole blood filter supplied as a component to the companies that make blood collection sets. The process uses no organic solvents and produces no process wastewater; the figures are on our sustainability page.

About Sangtech Lab Inc.

Sangtech Lab Inc. develops and manufactures CellNet™ filter media and semi-finished filters for medical device manufacturers and research facilities. Its patented supercritical CO₂ process modifies filtration media without water or solvents. Sangtech is headquartered in Taipei, with manufacturing in Yilan, Taiwan, and its team has worked on blood filtration since 1991.

Media contact

PR Team
Contact form
+886 2 2891 8099

Press kit available on request.

Sources

  1. ISBT. ISBT Kuala Lumpur 2026: 39th International Congress of the ISBT, June 20–24, 2026, Kuala Lumpur Convention Centre, with the Malaysian Blood Transfusion Society. Link
  2. A novel supercritical CO₂ modified leukoreduction filter with enhanced microparticle removal. Abstract, ISBT 2026 congress abstracts, Vox Sanguinis, 2026. Link
  3. Sangtech Lab Inc. Poster P388, “A Novel Supercritical CO₂-Modified Leukoreduction Filter with Enhanced Microparticle Removal”, 39th International Congress of the ISBT, Kuala Lumpur, June 2026 (manufacturer data).
  • Events
  • Research
  • CellNet™ PR
Source 1

ISBT. ISBT Kuala Lumpur 2026: 39th International Congress of the ISBT, June 20–24, 2026, Kuala Lumpur Convention Centre, with the Malaysian Blood Transfusion Society.

See all sources
Source 2

A novel supercritical CO₂ modified leukoreduction filter with enhanced microparticle removal. Abstract, ISBT 2026 congress abstracts, Vox Sanguinis, 2026.

See all sources
Source 3

Sangtech Lab Inc. Poster P388, “A Novel Supercritical CO₂-Modified Leukoreduction Filter with Enhanced Microparticle Removal”, 39th International Congress of the ISBT, Kuala Lumpur, June 2026 (manufacturer data).

See all sources

Request the technical brochure

Our team will email it to you.

I work at a…
Interested in Optional